Sign Up
Stories
ARMGO Pharma's Positive Trial Results
Share
ARMGO Pharma Receives $1 Million Award f...
Advancements in Cancer Treatment and Mar...
Advancing ALS Treatment through Protein ...
4D Molecular Therapeutics Raises $300 Mi...
ACTICOR BIOTECH Delays Key Documents
AMX0035 for PSP: Phase 3 Trial Commences
Overview
API
ARMGO Pharma's Phase 1b trial for Rycal ARM210 shows promising results for treating RYR1-RM, a rare muscle disease. The company has received orphan drug designation and is collaborating with NINDS and NIH. The RYR-1 Foundation supports this initiative.
Ask a question
How does the support from the RYR-1 Foundation contribute to the advancement of treatments for RYR1-RM and related diseases?
How might ARMGO Pharma's positive trial results impact the treatment landscape for RYR1-RM and related diseases?
What are the potential implications of ARMGO Pharma's collaboration with NINDS and NIH for future research and development in rare diseases?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage